VIR-7831 for the Early Treatment of COVID-19 in Outpatients

• Status: Completed
• Trial end date: 2021-09-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vir Biotechnology, Inc.
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old

• Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of symptoms

Exclusion Criteria:

• Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours

• Symptoms consistent with severe COVID-19

• Participants who, in the judgement of the investigator are likely to die in the next 7 days

• Severely immunocompromised participants